Key result
The SARS-CoV-2 S:A222V mutation promotes increased RBD opening and slightly increases ACE2 binding compared to the S:D614G clade, without reducing sera neutralization capacity.
Why the study?
The reappearance of the SARS-CoV-2 spike point mutation S:A222V in the Delta subvariant AY.4.2 raised questions regarding its specific effect on viral infection.
Answers are grounded in this paper and cite their sources.
The SARS-CoV-2 S:A222V mutation increases RBD opening and ACE2 binding but does not compromise vaccine-induced neutralization.
The S:A222V point mutation, within the G clade, was characteristic of the 20E (EU1) SARS-CoV-2 variant identified in Spain in early summer 2020. This mutation has since reappeared in the Delta subvariant AY.4.2, raising questions about its specific effect on viral infection. We report combined serological, functional, structural and computational studies characterizing the impact of this mutation. Our results reveal that S:A222V promotes an increased RBD opening and slightly increases ACE2 binding as compared to the parent S:D614G clade. Finally, S:A222V does not reduce sera neutralization capacity, suggesting it does not affect vaccine effectiveness.
No takes yet. Share an insight, caveat, or question.
Ginex et al. (2022) studied SARS-CoV-2. S:A222V mutation vs. Parent S:D614G clade was evaluated on RBD opening, ACE2 binding, and sera neutralization capacity. The SARS-CoV-2 S:A222V mutation promotes increased RBD opening and slightly increases ACE2 binding compared to the S:D614G clade, without reducing sera neutralization capacity.
Synapse has enriched 10 related papers. Consider them for comparative context: